1. FDA to review Teva and Alvotech's AVTO6 eye disorder treatment. 2. AVTO6 is a biosimilar aiming to compete with Eylea. 3. Eylea's U.S. sales reached $4.77 billion in 2024. 4. Teva and Alvotech have partnered since 2020 for biosimilars. 5. Alvotech shares saw a slight decline post-announcement.
FDA review is a positive signal for ALVO's future growth potential. Similar past cases have lifted stock prices upon regulatory approvals.
The FDA's review of a significant product suggests potential for market competition and profitability. With Eylea's substantial sales figures, AVTO6 could capture a notable market share.
Market reaction to the FDA news will likely influence ALVO's price immediately. Regulatory milestones often lead to short-term volatility in biotech stocks.